PM
VRTX icon

Prosight Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Prosight Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,500
Closed -$8.03M – 52
2025
Q3 		$8.03M Buy
+20,500
New +$8.57M 1.87% 21
2021
Q4 		– Sell
-15,000
Closed -$2.72M – 51
2021
Q3 		$2.72M Sell
15,000
-12,100
-45% -$2.36M 1.5% 24
2021
Q2 		$5.46M Sell
27,100
-11,250
-29% -$2.35M 3.42% 9
2021
Q1 		$8.24M Buy
38,350
+9,450
+33% +$2.08M 6.75% 2
2020
Q4 		$6.83M Buy
+28,900
New +$6.63M 3.16% 12

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Prosight Management's VRTX Position: Q4 2025 in Review

Prosight Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 20,500 shares — an estimated $8.03M sold.

Prosight Management first reported a position in VRTX in Q4 2020 and held it in 5 quarters. The position peaked at $8.24M in Q1 2021. 1,668 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Prosight Management reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Prosight Management sold 20,500 Vertex Pharmaceuticals shares in Q4 2025, an estimated $8.03M.
  • Prosight Management first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 5 quarters.
  • Prosight Management's Vertex Pharmaceuticals position peaked at $8.24M in Q1 2021.
  • 1,668 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Prosight Management's 13F filing for Q4 2025, filed 13 Feb 2026.